Nexgel has named Brian Kieser as interim CEO and formed a special committee to assess strategic alternatives and asset optimization following its BioNX acquisition. This leadership transition signals a strategic pivot to enhance liquidity and shareholder value, a development relevant to investor sentiment regarding the company's operational direction.